Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Iamarangerboy who wrote (9664)	8/29/2006 2:33:21 PM
From: Iamarangerboy	Read Replies (1) \| Respond to of 10280

Press Release Source: Sepracor Inc. Sepracor Announces Presentation of Arformoterol Data at the European Respiratory Society Annual Congress Tuesday August 29, 7:00 am ET MARLBOROUGH, Mass.--(BUSINESS WIRE)--Aug. 29, 2006--Sepracor Inc. (Nasdaq: SEPR - News) today announced that clinical data for arformoterol tartrate inhalation solution will be presented at the annual conference of the European Respiratory Society, which will be held at the International Congress Center Munich in Munich, Germany, September 2-6, 2006. Four posters will be presented. Please note the presentation date, time and location below: TITLE POSTER # DATE TIME LOCATION ---------------------------------------------------------------------- Efficacy of nebulized P1276 Sunday, 12:50- Hall B2-10 arformoterol, a long- September 3 14:40 acting beta(2)-adrenergic bronchodilator, in patients with COPD ---------------------------------------------------------------------- Arformoterol in COPD: P2500 Monday, 12:50- Hall B2-11 safety results from two September 4 14:40 pooled Phase 3 trials ---------------------------------------------------------------------- Exposure-response P2498 Monday, 12:50- Hall B2-11 relationship for nebulized September 4 14:40 arformoterol in subjects with COPD ---------------------------------------------------------------------- Population pharmacokinetics P2499 Monday, 12:50- Hall B2-11 of nebulized arformoterol September 4 14:40 in subjects with COPD ---------------------------------------------------------------------- About Arformoterol A New Drug Application (NDA) for arformoterol tartrate inhalation solution remains under review at the U.S. Food and Drug Administration (FDA). The NDA for arformoterol tartrate was submitted to the FDA in December 2005 and was accepted for filing by the FDA in February 2006. Arformoterol tartrate is a long-acting beta-agonist formulation, submitted for approval for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Arformoterol, a single isomer of formoterol, is the first long-acting bronchodilator to be developed in an inhalation solution for use with a nebulizer, which is a machine that converts liquid medication into a fine mist that is inhaled through a mask; other long-acting bronchodilators currently available are formulated in dry-powder inhalers.